Dec. 16 at 12:14 PM
Wedbush Added
$TYRA to their Best Idea List while⬆️the PT to
$37 from
$30 and reiterating at an Outperform rating.
$URGN $JNJ $BBIO $ASND SNY BMRN
Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to
$37 (from
$30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
